Skip to main content

Table 4 Association analyses of the -1154G > A VEGF polymorphism in endometriosis patients compared with women without disease

From: Role of vascular endothelial growth factor polymorphisms (-2578C > A, -460 T > C, -1154G > A, +405G > C and +936C > T) in endometriosis: a case–control study with Brazilians

-1154G > A

Controls

Cases

OR (95% IC)b

DIE Cases

OR (95% IC)c

Stages III-IV

OR (95% IC)d

(n = 106)

(n = 161)

(n = 131)

(n = 97)

N (%)

N (%)

N (%)

N (%)

Genotypes

       

GG

74 (69.8)

90 (55.9)

1a

75 (57.3)

1a

56 (57.7)

1a

GA

30 (28.3)

56 (34.8)

1.54 (0.90 - 2.63)

44 (33.6)

1.45 (0.82 - 2.54)

29 (29.9)

1.28 (0.69 - 2.37)

AA

2 (1.9)

15 (9.3)

6.17 (1.37 - 27.8)

12 (9.1)

5.92 (1.28 - 27.4)

12 (12.4)

7.93 (1.70 - 36.9)

Non-GG (GA + AA)

32 (30.2)

71 (44.1)

1.82 (1.09 - 3.06)

56 (42.7)

1.73 (1.01 - 2.96)

41 (42.3)

1.69 (0.95 - 3.02)

Allele

       

G

178 (84.0)

236 (73.3)

1a

194 (74.1)

1a

141 (72.7)

1a

A

34 (16.0)

86 (26.7)

1.90 (1.23 - 2.97)

68 (25.9)

1.83 (1.16 - 2.90)

53 (27.3)

1.97 (1.21 - 3.19)

  1. OR is odds ratio, CI is confidence interval. aReference Group; bControls vs. Cases (All patients with endometriosis); cControls vs. Deeply infiltrating endometriosis patients (DIE); dControls vs. Moderate or severe endometriosis patients (stages III or IV). Due to insufficient DNA samples, some of the patients were not genotyped for -1154G > A SNP.